Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hsu

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
BMC Cancer|November 3, 2019
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerJohn H Strickler, Christel N Rushing, Donna Niedzwiecki, et al.
The Oncologist|January 20, 2021
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal CancerJohn H Strickler, Christel N Rushing, Hope E Uronis, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 11, 2021
Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 AxisLihua Wang, Ergang Wang, Jorge Prado Balcazar, et al.
Investigational New Drugs|April 9, 2014
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumorsFatima Rangwala, Johanna C Bendell, Mark F Kozloff, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 21, 2024
Chromatin Remodeling in Patient-Derived Colorectal Cancer ModelsKun Xiang, Ergang Wang, John Mantyh, et al.
Nature Biotechnology|July 4, 2012
A hybrid approach for the automated finishing of bacterial genomesAli Bashir, Aaron Klammer, William P Robins, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
Annals of Surgical Oncology|January 18, 2025
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Annals of Surgical Oncology|January 28, 2025
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Cell Stem Cell|May 4, 2022
Patient-derived micro-organospheres enable clinical precision oncologyShengli Ding, Carolyn Hsu, Zhaohui Wang, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
BMC Cancer|November 3, 2019
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerJohn H Strickler, Christel N Rushing, Donna Niedzwiecki, et al.
The Oncologist|January 20, 2021
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal CancerJohn H Strickler, Christel N Rushing, Hope E Uronis, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 11, 2021
Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 AxisLihua Wang, Ergang Wang, Jorge Prado Balcazar, et al.
Investigational New Drugs|April 9, 2014
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumorsFatima Rangwala, Johanna C Bendell, Mark F Kozloff, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 21, 2024
Chromatin Remodeling in Patient-Derived Colorectal Cancer ModelsKun Xiang, Ergang Wang, John Mantyh, et al.
Nature Biotechnology|July 4, 2012
A hybrid approach for the automated finishing of bacterial genomesAli Bashir, Aaron Klammer, William P Robins, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
Annals of Surgical Oncology|January 18, 2025
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Annals of Surgical Oncology|January 28, 2025
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Cell Stem Cell|May 4, 2022
Patient-derived micro-organospheres enable clinical precision oncologyShengli Ding, Carolyn Hsu, Zhaohui Wang, et al.
Pageof 14